Skip to main content
SpringerLink
Log in

Nuovi farmaci inibitori selettivi di RET (selpercatinib e pralsetinib) nei pazienti con carcinoma midollare della tiroide avanzato

  • FARMACI INNOVATIVI IN ENDOCRINOLOGIA
  • Published:
L'Endocrinologo Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Bibliografia

  1. Vogelstein B, Papadopoulos N, Velculescu VE et al. (2013) Cancer genome landscapes. Science 339(6127):1546–1558

    Article  CAS  Google Scholar 

  2. Ciampi R, Romei C, Ramone T et al. (2019) Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing. iScience 20:324–336

    Article  CAS  Google Scholar 

  3. Elisei R, Tacito A, Ramone T et al. (2019) Twenty-five years experience on RET genetic screening on hereditary MTC: an update on the prevalence of germline RET mutations. Genes (Basel) 10(9):698

    Article  CAS  Google Scholar 

  4. Romei C, Casella F, Tacito A et al. (2016) New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations. J Med Genet 53(11):729–734

    Article  CAS  Google Scholar 

  5. Moura MM, Cavaco BM, Pinto AE et al. (2009) Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer 100(11):1777–1783

    Article  CAS  Google Scholar 

  6. Viola D, Valerio L, Molinaro E et al. (2016) Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocr-Relat Cancer 23(4):R185–R205

    Article  CAS  Google Scholar 

  7. Herrmann J (2016) Tyrosine kinase inhibitors and vascular toxicity: impetus for a classification system? Curr Oncol Rep 18(6):33

    Article  Google Scholar 

  8. Subbiah V, Velcheti V, Tuch BB et al. (2018) Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol 29(8):1869–1876

    Article  CAS  Google Scholar 

  9. Subbiah V, Gainor JF, Rahal R et al. (2018) Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov 8(7):836–849

    Article  CAS  Google Scholar 

  10. Wirth LJ, Sherman E, Robinson B et al. (2020) Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 383(9):825–835

    Article  CAS  Google Scholar 

  11. Wells SA, Robinson BG, Gagel RF et al. (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30(2):134–141

    Article  CAS  Google Scholar 

  12. Elisei R, Schlumberger MJ, Müller SP et al. (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31(29):3639–3646

    Article  CAS  Google Scholar 

  13. Hu M, Subbiah V, Wirth LJ et al. (2020) 1913O results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (\(\text{RET}+ \text{MTC}\)). Ann Oncol 31:S1084

    Article  Google Scholar 

  14. Solomon BJ, Tan L, Lin JJ et al. (2020) RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies. J Thorac Oncol 15(4):541–549

    Article  CAS  Google Scholar 

  15. Subbiah V, Shen T, Terzyan SS et al. (2021) Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol 32(2):261–268

    Article  CAS  Google Scholar 

  16. Lin JJ, Liu SV, McCoach CE et al. (2020) Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann Oncol 31(12):1725–1733

    Article  CAS  Google Scholar 

  17. Rosen EY, Johnson ML, Clifford SE et al. (2021) Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib. Clin Cancer Res 27(1):34–42

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unità di Endocrinologia, Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Pisa, Italia

    Alessandro Prete, Rossella Elisei & Antonio Matrone

Authors
  1. Alessandro Prete
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rossella Elisei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonio Matrone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alessandro Prete.

Ethics declarations

Conflitto di interesse

Rossella Elisei è consulente per Bayer, Eisai, Astra Zeneca, Exilixis, Genzyme ma tale attività non ha influenzato questo lavoro.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo studio non hanno eseguito studi sugli animali.

Additional information

Nota della casa editrice

Springer Nature rimane neutrale in riguardo alle rivendicazioni giurisdizionali nelle mappe pubblicate e nelle affiliazioni istituzionali.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Prete, A., Elisei, R. & Matrone, A. Nuovi farmaci inibitori selettivi di RET (selpercatinib e pralsetinib) nei pazienti con carcinoma midollare della tiroide avanzato. L'Endocrinologo 22, 574–575 (2021). https://doi.org/10.1007/s40619-021-00992-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-021-00992-4

Search

Navigation